Abbott, Biogen report MS drug reduced relapse rate BusinessWeek Biogen Idec and Abbott Laboratories said Sunday a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing relapse of symptoms of the inflammatory disease. ... ECTRIMS: New Biologic Drug Shows Promise in MS |
